SS-31 / Elamipretide 10mg

SS-31, also known as Elamipretide, is a mitochondrial-targeting peptide currently under investigational research. It is designed to selectively accumulate in the inner mitochondrial membrane, where it interacts with cardiolipin, a phospholipid crucial for mitochondrial function. This interaction is believed to protect mitochondria from oxidative damage and improve their efficiency.

In research models, SS-31 has been explored for its potential in various contexts where mitochondrial dysfunction is implicated. Its unique mechanism of action focuses on restoring mitochondrial integrity and function, which are vital for cellular energy production and overall cellular health. Researchers are investigating its effects on cellular respiration, ATP production, and the reduction of reactive oxygen species within mitochondria.

Mechanism of Action

SS-31 primarily functions by targeting the inner mitochondrial membrane. It binds to cardiolipin, a negatively charged phospholipid predominantly found in this membrane. This binding is thought to stabilize the cardiolipin structure, which in turn helps to maintain the integrity of the mitochondrial cristae and optimize electron transport chain activity. By improving cardiolipin-cytochrome c interaction, SS-31 enhances mitochondrial respiration and reduces the production of reactive oxygen species, thereby mitigating oxidative stress within the mitochondria. This action helps to restore mitochondrial bioenergetics and protect against mitochondrial dysfunction.

Structure and Class

SS-31 is a small, water-soluble tetrapeptide with the amino acid sequence D-Arg-Dmt-Lys-Phe-NH2 (where Dmt is 2',6'-dimethyltyrosine). This specific sequence provides it with its mitochondrial-targeting properties and its ability to interact with cardiolipin. It is classified as a mitochondrial-targeting peptide (MTP) and a cell-penetrating peptide. Its D-amino acid configuration provides resistance to enzymatic degradation, contributing to its stability and biological half-life in research settings.

Primary Research Areas

Researchers are investigating SS-31 across a broad spectrum of conditions characterized by mitochondrial dysfunction and oxidative stress. Key research areas include cardiovascular diseases, such as myocardial ischemia-reperfusion injury and heart failure, where compromised mitochondrial function plays a significant role. It is also being studied in models of kidney disease, neurodegenerative disorders like Parkinson's and Alzheimer's disease, and various age-related conditions. Additionally, its potential role in addressing metabolic disorders and skeletal muscle pathologies is under exploration.

Notable Peer-Reviewed Findings

In experimental models of acute kidney injury, SS-31 has been shown to protect mitochondrial structure and function, reducing oxidative stress and improving renal outcomes. Investigational studies in cardiovascular research have indicated that SS-31 can ameliorate mitochondrial dysfunction in heart failure models, leading to improved cardiac function and reduced pathological remodeling. Furthermore, in models of neurodegenerative diseases, peer-reviewed findings suggest that SS-31 may enhance mitochondrial bioenergetics and reduce neuronal damage by preserving mitochondrial integrity and function. These findings highlight its therapeutic potential in conditions associated with mitochondrial compromise.